Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

VELOUR studies are anticipated in the first half of 2011.  Based on projected event rates, an interim analysis of the VENICE study is expected to be conducted by an Independent Data Monitoring Committee in mid-2011, with final results anticipated in 2012.  

In addition, a randomized Phase 2 study (AFFIRM) is evaluating aflibercept as a 1st-line treatment for metastatic colorectal cancer in combination with FOLFOX (folinic acid [leucovorin], 5-fluorouracil, and oxaliplatin).  The AFFIRM study is fully enrolled, and initial data are anticipated in the second half of 2011.

Monoclonal AntibodiesSince 2007, Regeneron and sanofi-aventis have collaborated on the discovery, development, and commercialization of fully human monoclonal antibodies generated by Regeneron using its VelocImmune® technology.  During the fourth quarter of 2009, Regeneron and sanofi-aventis expanded and extended their collaboration with the objective to advance an average of four to five antibodies into clinical development each year between 2010 and 2017.  The following eight antibody candidates are currently in clinical development under the collaboration:

REGN727, an antibody to Proprotein Convertase Substilisin/Kexin type 9 (PCSK9), a novel target for LDL cholesterol ("bad cholesterol") reduction, has been evaluated in Phase 1 studies using both intravenous and subcutaneous routes of administration.  REGN727 is being studied as a single agent and in combination with statin therapy.  Phase 2 studies have been initiated in patients with hypercholesterolemia.  

REGN88, an antibody to the interleukin-6 receptor (IL-6R), is in a Phase 2/3 study in rheumatoid arthritis and a Phase 2 study in ankylosing spondylitis, a form of arthritis that primarily affects the spine.  Both studies are enrolling patients, and initial Phase 2 results are expected in 2011.

REGN421, an antibody to
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SOUTH SAN FRANCISCO, Calif. , March 2, ... therapeutics for the treatment of cancer, today announced ... comprised of leading researchers and clinicians in the ... The new advisory boards will ... its wholly owned pipeline of precision immunotherapies and ...
(Date:3/2/2015)... , March 2, 2015   Mast ... biopharmaceutical company, today announced preliminary findings from a ... a model of chronic, stable heart failure produced ... study was to examine the effects of repeat ... systolic and diastolic function. Consistent ...
(Date:3/2/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... will participate in the upcoming 27 th Annual ... the Ritz Carlton Laguna Niguel in Dana ... MSN, CRNP, Delcath,s interim President and Chief Executive Officer, ...
Breaking Medicine Technology:CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3
... The Epilepsy Foundation recently announced findings that show ... a consistent drug therapy, have a greater chance of ... their medications are switched from one version of an ... brand-to-generic, generic-to-brand or generic-to-generic. See video from the Epilepsy ...
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
Cached Medicine Technology:VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful 2Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... 02, 2015 Regulatory Compliance Associates® ... quality, regulatory and technical consulting, announces Mr. Seyed ... Officer. , Before joining RCA, Mr. Khorashahi ... teams in all aspects of developing safety-critical medical ... Covidien (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, ...
(Date:3/2/2015)... 02, 2015 The Alliance for Bangladesh ... expert Mark Chubb to serve as chief safety officer. ... and training in Bangladesh and guide remediation efforts in ... “Mark will ensure that the Alliance continues to bring ... for Bangladesh garment workers,” said Alliance Independent Chair Ellen ...
(Date:3/2/2015)... 2015 Final Cut Pro X ... 2 from Pixel Film Studios. , “The TranStatic Volume 2 ... said Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume ... Cut Pro X editors toolbox.” , With TranStatic Volume 2 ... media altering static scrambling effects from Pixel Film Studios. Users ...
(Date:3/1/2015)... As residents and business owners in ... and Carita Weaver, believe in supporting local organizations ... Southlake Chamber of Commerce, Carroll Independent School District ... a website for Southlake mayoral candidate Laura Hill: ... for Hill’s campaign, the website combines images, videos ...
Breaking Medicine News(10 mins):Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2
... older women with breast cancer lag behind younger women diagnosed ... missing out on improvements in treatment and detection, according to ... Center. The study, published in the Journal of ... whether the improvements made in breast cancer outcomes over the ...
... 2011) AMRI (NASDAQ: AMRI) announced today that, as ... and Company, it anticipates hiring more than 40 synthetic ... Lilly,s drug discovery programs. The chemists will work onsite ... support the medicinal chemistry department. This collaboration will ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. ... child with autism or with a milder form of ... only by the child,s symptoms, but by where the ... found wide variability at autism centers across the nation ...
... CA The University of California, Santa Barbara ... Grand Challenges Explorations, an initiative created by the ... worldwide to test unorthodox ideas that address persistent ... Amr El Abbadi in the Computer Science Department ...
... The Lymphoma Division of the John Theurer Cancer Center at ... groups "Hope for Lymphoma" and "Our MCL Family," will host ... from 8:30am 3:45pm. The event is open to ... patients and their caregivers coping with this challenging diagnosis. ...
... HealthDay Reporter , SUNDAY, Nov. 6 (HealthDay News) -- ... the holiday season for some. For others, those airborne ... and sneezing to asthma attacks. Allergists say as ... complaints from their patients about reactions to them. ...
Cached Medicine News:Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 2Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 3Health News:Where a Child Is Tested May Affect Autism Diagnosis 2Health News:Where a Child Is Tested May Affect Autism Diagnosis 3Health News:UC Santa Barbara receives Grand Challenges Explorations funding 2Health News:UC Santa Barbara receives Grand Challenges Explorations funding 3Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Murphy eye-nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Medicine Products: